home / stock / pulm / pulm short
Short Information | Pulmatrix Inc. (NASDAQ:PULM)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 96,545 |
Total Actual Volume | 390,469 |
Short Trends | |
---|---|
Cover Days | 15 |
Short Days | 1 |
No Change Days | 4 |
Averages | |
---|---|
Average Short Volume | 4,827 |
Average Short Percentage | 23.91% |
Is there a PULM Short Squeeze or Breakout about to happen?
See the PULM Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-19-2024 | $2.0294 | $1.9897 | $2.04 | $1.91 | 11,844 | 1,528 | 12.9% |
04-18-2024 | $2.06 | $1.96 | $2.09 | $1.91 | 31,035 | 1,695 | 5.46% |
04-17-2024 | $2.08 | $2.09 | $2.11 | $2.0594 | 3,684 | 266 | 7.22% |
04-16-2024 | $2.08 | $2.12 | $2.19 | $2.08 | 6,129 | 2,378 | 38.8% |
04-15-2024 | $2.16 | $2.09 | $2.18 | $2.08 | 5,271 | 613 | 11.63% |
04-12-2024 | $2.141 | $2.16 | $2.19 | $2.05 | 26,202 | 18,890 | 72.09% |
04-11-2024 | $1.95 | $2.1 | $2.15 | $1.95 | 62,527 | 17,160 | 27.44% |
04-10-2024 | $1.82 | $1.9 | $1.99 | $1.8 | 18,565 | 1,564 | 8.42% |
04-09-2024 | $1.94 | $1.91 | $1.94 | $1.8601 | 1,900 | 492 | 25.89% |
04-08-2024 | $1.99 | $1.89 | $2.03 | $1.89 | 16,562 | 3,878 | 23.42% |
04-05-2024 | $1.7262 | $2.009 | $2.06 | $1.7262 | 88,038 | 13,950 | 15.85% |
04-04-2024 | $1.8 | $1.8784 | $1.93 | $1.8 | 35,588 | 14,828 | 41.67% |
04-03-2024 | $1.775 | $1.81 | $1.8656 | $1.765 | 5,296 | 2,316 | 43.73% |
04-02-2024 | $1.75 | $1.71 | $1.75 | $1.68 | 3,278 | 723 | 22.06% |
04-01-2024 | $1.7 | $1.74 | $1.8 | $1.7 | 8,462 | 490 | 5.79% |
03-28-2024 | $1.65 | $1.75 | $1.85 | $1.5601 | 39,041 | 9,839 | 25.2% |
03-27-2024 | $1.68 | $1.62 | $1.7 | $1.62 | 11,761 | 3,006 | 25.56% |
03-26-2024 | $1.69 | $1.6907 | $1.7 | $1.63 | 4,676 | 1,874 | 40.08% |
03-25-2024 | $1.68 | $1.67 | $1.68 | $1.64 | 7,597 | 503 | 6.62% |
03-22-2024 | $1.59 | $1.67 | $1.67 | $1.59 | 3,013 | 552 | 18.32% |
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update PR Newswire 2023 year-end $19.2 million cash and cash equivalents provide projected cash runway into Q1 2026 3 rd amendment to Cipla partnership resulted in the wind down o...
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives PR Newswire Cipla to take sole responsibility for development of PUR1900, refocu...
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Patient enrollment for the Phase 2b study of PUR1900 is ongoing with four additional sites added during Q3, totaling seventeen active sites to date in four countries; topline...